Highlights from the 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA. June 2004.
Lee
David
D
Price
Nancy
N
Reddy
Kesava
K
D000328:Adult; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000077868:Atrasentan; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D006801:Humans; D008297:Male; D008495:Medical Oncology; D008875:Middle Aged; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D011759:Pyrrolidines / Q000008:administration & dosage*; D011788:Quality of Life; D018570:Risk Assessment; D012955:Societies, Medical; D016019:Survival Analysis; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D011759:Pyrrolidines; D000077868:Atrasentan